WHO ICTRP trial
Diagnostic value of detection of PCA3 and PSA gene expression in morning urine…
ChiCTR2500114093 · Chinese Clinical Trial Registry (ChiCTR) · Not Recruiting
Key facts
| Trial ID | ChiCTR2500114093 |
|---|---|
| Public title | Diagnostic value of detection of PCA3 and PSA gene expression in morning urine (fluorescence PCR) for people suspected of prostate cancer |
| Scientific title | Diagnostic value of detection of PCA3 and PSA gene expression in morning urine (fluorescence PCR) for people suspected of prostate cancer |
| Primary sponsor | Beijing Shijitan Hospital, Capital Medical University |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Not Recruiting |
| Study type | Diagnostic test |
| Countries | China |
| Conditions | prostatic cancer |
| Interventions | Gold Standard:Prostate biopsy;Index test:Detection of PCA3 and PSA gene expression in morning urine (fluorescence PCR) |
| Registration date | Dec 8, 2025 |
| Target size | Target condition:80;Difficult condition:80 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: